Advertise on podcast: Deep Dive In Vitiligo

Pregnancy has a way of ignoring project plans. Add vitiligo to the mix, and suddenly Google becomes a scary place full of outdated advice and medical catastrophizing. In this episode of Deep Dive in Vitiligo, we take a honest, scientifically grounded look at what happens to your skin before, during, and after baby arrives. From medication safety and postpartum flares to thyroid checks and genetic inheritance myths, we’re cutting through the noise with reassuring, practical answers every mom-to-be needs to hear. In this episode, we discuss: How pregnancy actually affects vitiligo activity (and why most women stay stable) What the latest studies say about pregnancy risks and thyroid health Navigating topicals, light therapy, and new treatments like Opzelura The real genetic odds of passing vitiligo to your child Whether you’ve been carefully planning for months or just stared in shock at a positive test on a Tuesday morning, pull up a chair—this is your ultimate, no-panic guide to navigating pregnancy with vitiligo. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode: Pregnancy and Vitiligo

A paused drug program. A reasonable suspicion. Then the question under it: why is there still no cure? In this episode, Yan Valle argues there is no hidden pill in a glass tower. Companies are not charities, and they are not sitting on a cure because a chronic treatment pays better. The harder account is ordinary. Academia funds what it can publish. Biotech bets on the next round. Pharma keeps what can survive the regulators and the market. Insurers pay for this year’s budget. Patients inherit the sum. A program can die before anyone knows if the biology was right — a bet on another bet, ten years out, before the casino is built. Early treatment of active vitiligo sounds obvious, and still loses to step therapy and a planning horizon shorter than a child’s year. The price on the receipt was not set by one hand. And “they buried the cure” is easier to air than a system with no villain. Misconduct is real. This is not a defense of it. But systems before conspiracy is usually the better place to start. The full essay is on the VRF site. Ten minutes. A double coffee is welcome.

Your skin may enter the room first. Your job is to make sure your work takes over the conversation. Visible vitiligo does not change competence. It can still change interviews, promotions, and how “professional” gets judged — especially when the face is involved. That is a social problem, not a skills problem. Social problems need strategy, boundaries, and sometimes a little documentation. In this episode we cover the unglamorous playbook: how to build a case instead of a vibe, what to say if someone stares or asks the wrong question, when disclosure helps and when it doesn’t, and which workplace protections may apply in the US and the UK. Bias exists. So do portfolios, notes, and the right to leave. Your skin is not the product. Prefer reading to listening? The companion article expands on the themes in this episode: Career Success with Visible Vitiligo.

Fifteen years ago, keeping up with vitiligo news was easy. There simply wasn’t that much of it. Today, research, clinical trials, industry updates, patient discussions, and AI-generated answers arrive faster than anyone can realistically process them. In Episode 78 of Deep Dive in Vitiligo, we look at what happens next: people stop searching, comparing, and opening twenty browser tabs — and start asking AI to do the thinking for them. That shift has a name: cognitive surrender. We explore why handing part of the decision-making process to ChatGPT and other AI tools can be perfectly rational, where it becomes risky, and why pharma companies, doctors, and patient organizations suddenly need to care about what AI says when someone asks a very simple question: “What are my options?” AI may be both the cause of the information flood and our best tool for navigating it. Just don’t let it out of the fire pit. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode. 15 Years of Vitiligo News Publication

What changes when vitiligo puts on a uniform? The disease stays the same. Almost everything around it changes — from medical fitness and deployment to treatment access, military records, VA care, and disability claims. In this episode of Deep Dive in Vitiligo, we follow the patient journey from sick call to civilian care and examine where people, records, and responsibility can fall through the cracks. We also separate three questions that are too often mixed together: Can someone join? Can they remain in service? And did military service cause or aggravate the condition? We close with a preview of Massé World’s Honor Without Exception, a free symposium bringing service members, veterans, clinicians, researchers, and policymakers together in Miramar, Florida, on November 14, 2026. Same skin condition. Different rules. Much higher stakes. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

Durante años, la crema aprobada se detenía a los 12. Los más pequeños se quedaban con el menú de siempre: corticoides, tacrolimus, luz si había hueco, y mucha espera. Eso empieza a cambiar. Hay dos ensayos de fase 3 con crema de ruxolitinib — Opzelura, si ya conoces el tubo — en niños con la forma más común de vitíligo. Protocolos de verdad. Centros de verdad. No un rumor de un grupo de padres. El matiz: no son el mismo estudio. Si los mezclas, una familia reserva viaje al continente equivocado. En este episodio de *Deep Dive in Vitiligo* ponemos los dos ensayos uno al lado del otro. Vas a escuchar: El ensayo norteamericano TRuE-ViP (NCT06548360): de 2 a 11 años, Estados Unidos y Canadá, unos 180 niños El ensayo internacional (NCT06804811, Incyte INCB18424-309): a partir de los 6 años, Argentina más 13 países europeos, unos 250 niños, sin centros en EE. UU. ni Canadá Lo que comparten: solo vitíligo no segmentario, un techo del 10% de superficie corporal, crema vehículo las primeras 24 semanas, la cara como medida principal en la semana 24, y la obligación de pausar otros tratamientos para el vitíligo, incluida la fototerapia Por qué un niño de 8 años puede cumplir la edad en los dos y no encajar en ninguno por código postal No suspendas un tratamiento que ya funciona porque en la misma semana aparecieron dos páginas de ensayo. Pregunta en el centro qué habría que pausar. Después llama al dermatólogo habitual del niño. Sí es una respuesta razonable. No también. La pregunta útil es qué protocolo — si es que alguno — encaja con este niño, en este país, con esta agenda.

For years, approved ruxolitinib cream has stopped at age 12. Younger children have had a much shorter menu: steroids, tacrolimus, light therapy if you can get a slot, and a lot of waiting. Now two Phase III studies are evaluating ruxolitinib cream in younger children. Its use for vitiligo in these age groups is investigational — researchers are still finding out how well it works and how safe it is. Real protocols. Real sites. Not a rumor from a parent group. Then the catch: they are not the same study. Mix them up and a family books the wrong continent. In this episode of Deep Dive in Vitiligo, we put the trials side by side. You’ll hear: North American trial TRuE-ViP (NCT06548360) — ages 2 to 11, United States and Canada The international trial (NCT06804811, Incyte INCB18424-309) — starts at age 6, Argentina plus 13 European countries, no U.S. or Canadian sites What they share: nonsegmental vitiligo, a 10% body-surface ceiling, active-versus-vehicle treatment during the first 24 weeks, facial scoring at Week 24, and some restrictions. Why an 8-year-old can fit both studies by age and neither by postcode. Do not stop a working routine because two trial pages appeared in the same week. Ask the site what would pause. Then call the child’s regular dermatologist. Yes is a reasonable answer. No is a reasonable answer. The useful question is which protocol — if either — fits this child, in this country, with this schedule. Both studies discussed in this episode are sponsored by Incyte Corporation. VRF provides patient education and study-awareness support related to Incyte pediatric vitiligo research under a paid services agreement. VRF does not determine study eligibility or recommend participation. 📚 Prefer reading to listening? These two companion articles expand on many of the themes discussed in this episode. Vitiligo Study For Children Ages 2–11 in USA and Canada  Vitiligo Study For Children Ages 6-11, International

Most people think gloves are simple: put them on, protect your hands, move on with life. Unfortunately, your skin didn’t get that memo. In this episode of Deep Dive in Vitiligo, we explore the surprisingly complicated world of work gloves, hand dermatitis, chemical leukoderma, and the Koebner phenomenon. Why do some gloves trigger itching, cracking, or irritation? Why can friction matter almost as much as chemicals? And why are many dermatologists quietly steering patients toward accelerator-free nitrile gloves? We compare latex, vinyl, and nitrile options, discuss cotton and silk liners, tackle the rise of biodegradable “eco-friendly” gloves, and explain how a simple choice at the hardware store or workplace can affect long-term hand health. No fear-mongering. No glove industry conspiracies. Just practical advice to help your hands do their job without becoming part of the problem. Because the best glove is supposed to protect your skin — not give it a new hobby.  📚 Prefer reading to listening? The companion article expands on many of the themes discussed in this episode.

Not every vitiligo lesson has to come from a doctor’s office. In this episode of Deep Dive in Vitiligo, we explore some of the best children’s books about vitiligo—from heartfelt stories of self-acceptance to practical tools that help kids explain their skin to friends, classmates, and even themselves. We discuss how books can build confidence long before a child learns the medical terminology, and which titles are actually worth adding to your family library. Whether you’re a parent, grandparent, teacher, healthcare professional, or simply looking for a thoughtful gift, this episode offers a guided tour through the growing world of vitiligo literature for young readers. Because sometimes a story can do what a prescription cannot. ✨ 📚 Prefer reading to listening? The companion article expands on many of the themes discussed in this episode, with links to find these titles online.

Vitamin D matters in vitiligo. Megadoses? That’s where things get interesting — and risky. In this episode, we unpack the hype around high-dose vitamin D, the Coimbra Protocol, and the small Brazilian study that made patients pay attention. We cover the possible immune benefits, the real safety concerns — hypercalcemia, kidney stones, strict monitoring — and why correcting a deficiency is not the same as taking massive doses. Promising biology. Preliminary evidence. Poor safety. No miracle-cure fireworks. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

Patients used to Google their symptoms. Now they ask AI what the hell to do next. In this episode of Deep Dive in Vitiligo, we unpack “cognitive surrender” — that quiet moment when people stop wrestling the information jungle and just hand the steering wheel to an AI companion. For pharma, the old playbook is dead. Forget billboards, keywords, and glossy websites. The new arena is whether the AI understands, trusts, and actually recommends your therapy when a patient asks: “What are my real options for this vitiligo?” Less advertising. More droid advisor. Welcome to the future of pharmaceutical marketing — where the most important customer might not even be human anymore.   📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

Nails may seem like an unlikely place to look for clues about vitiligo — but science says otherwise. In this episode of Deep Dive in Vitiligo, we cut through the hype on the real, usually mild, connection between vitiligo and nail changes. Melanocytes live in the nail matrix too, so the same immune activity that affects skin pigment may sometimes leave tiny traces: vertical ridges, leukonychia, splinter hemorrhages, brittle nails, missing half-moons, or changes visible only through dermoscopy. We unpack the latest studies, explain what these findings may mean for patients, and discuss when nail changes deserve a closer look — and when they’re probably just part of being human. No panic. No self-diagnosis spirals. Just a fascinating look at one of the most overlooked corners of vitiligo science. 🔍💅 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

We’ve all seen the headlines: red wine might reduce vitiligo risk. Coffee keeps showing up as protective in the data. Berries, tea, and the usual Mediterranean suspects all look suspiciously useful. Sounds like good news — until you remember the supplement aisle packed with “super antioxidant” bottles that somehow never quite deliver. In this episode, we cut through the noise. Genetic studies hint at real signals from whole-food polyphenols and the messy, living matrix that comes with them — not lonely molecules trapped in capsules. We talk oxidative stress, why biology prefers a Swiss watch over a single gear, moderation (yes, even with wine), and why Prof. Torello Lotti’s famous final slide with a glass of Chianti still hits different. No miracle cures. No wellness hype. Just the practical, slightly inconvenient truth about food, context, and living like a human instead of a biochemistry experiment. Pour yourself something real — or don’t — and join the conversation.   📚 Prefer reading to listening? Two companion articles expand on many of the themes discussed in this episode:  Red Wine and Vitiligo: Helpful, Harmful, or Just Humans Looking for Good News? Why Berries, Coffee and Wine Work Better Than Antioxidant Capsules

Natural does not always mean helpful. In this episode of Deep Dive in Vitiligo, we flip the usual herbal medicine question on its head. Instead of asking "which herbs may help vitiligo", we ask something more uncomfortable: could some popular “immune boosters” be quietly working against repigmentation? We explore how herbs like ginseng, Bacopa monnieri, and licorice root may affect melanin production, tyrosinase activity, and the same pigment pathways many vitiligo treatments are trying to restore. This is not an anti-herb episode. It is a pro-chemistry episode. Because your melanocytes do not care whether something is natural, ancient, or wrapped in nice green packaging. They respond to biology. If you take supplements, drink herbal teas, use adaptogens, or apply “brightening” skincare products while treating vitiligo, this episode is worth your attention.   📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

Could your deodorant be making vitiligo worse? It’s a question that lands in our inbox surprisingly often — and one that turns out to be more complicated than a simple yes or no. In this episode of Deep Dive in Vitiligo, we explore the science behind deodorants, antiperspirants, fragrance allergies, chemical leukoderma, and why underarm skin may deserve more attention than most of us give it. There’s no solid evidence that ordinary deodorants or antiperspirants cause vitiligo. If your deodorant works, feels invisible, and causes no problems, carry on. But if it burns, itches, triggers eczema, or seems connected to new patches, your skin may be trying to tell you something. Tune in for the latest 2026 regulatory updates, including expanded EU fragrance labeling, the truth about the “whole-body deodorant” trend, and a practical routine to help keep your underarms calm. You’ll get a dead-simple testing protocol, the red-flag signs to stop yesterday, and a practical routine that respects real skin instead of wellness theater.   📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.